Aptamer Group PLC
Company Profile
Business description
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and other; Geographically earning maximum revenue from USA.
Contact
Innovation Way
Windmill House
YorkYO10 5BR
GBRT: +44 1904217404
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
34
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
stocks
Why Guzman and Reece's share reversals have a lot in common
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,143.92 | 92.85 | 1.15% |
DAX 40 | 22,794.11 | 383.84 | 1.71% |
Dow JONES (US) | 43,412.50 | 208.66 | -0.48% |
FTSE 100 | 8,731.46 | 62.79 | 0.72% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,089.08 | 62.69 | 0.33% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,957.19 | 1.94 | 0.03% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |